James Early Net Worth

The estimated Net Worth of James Early is at least $10.5 mil dollars as of 29 July 2020. James Early owns over 5,000 units of Interpace Biosciences Inc stock worth over $10,474 and over the last 8 years James sold IDXG stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

James Early IDXG stock SEC Form 4 insiders trading

James has made over 1 trades of the Interpace Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently James exercised 5,000 units of IDXG stock worth $7,350 on 29 July 2020.

The largest trade James's ever made was exercising 5,000 units of Interpace Biosciences Inc stock on 29 July 2020 worth over $7,350. On average, James trades about 625 units every 0 days since 2016. As of 29 July 2020 James still owns at least 7,125 units of Interpace Biosciences Inc stock.

You can see the complete history of James Early stock trades at the bottom of the page.

What's James Early's mailing address?

James's mailing address filed with the SEC is C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY, PARSIPPANY, NJ, 07054.

Insiders trading at Interpace Biosciences Inc

Over the last 9 years, insiders at Interpace Biosciences Inc have traded over $0 worth of Interpace Biosciences Inc stock and bought 94,105 units worth $353,961 . The most active insiders traders include Peter Kamin, Nat Krishnamurti, eGraham G Miao. On average, Interpace Biosciences Inc executives and independent directors trade stock every 99 days with the average trade being worth of $48,561. The most recent stock trade was executed by Thomas W. Burnell on 21 May 2021, trading 10,855 units of IDXG stock currently worth $94,221.

What does Interpace Biosciences Inc do?

advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.

Complete history of James Early stock trades at Interpace Biosciences Inc

Interpace Biosciences Inc executives and stock owners

Interpace Biosciences Inc executives and other stock owners filed with the SEC include:

• Jack Stover,
  President, Chief Executive Officer, Director
• Dr. Thomas W. Burnell Ph.D.,
  Pres, CEO & Director
• Fortunato Rocca,
  Independent Director
• Joseph Keegan,
  Independent Director
• Eric Lev,
  Non-Executive Director
• Robert Gorman,
  Director
• Edward Chan,
  Director
• Fred Knechtel,
  Chief Financial Officer, Treasurer, Secretary
• Stephen Sullivan,
  Chairman of the Board
• Patrick Kane,
  VP & Corp. Controller
• Dr. Alidad Mireskandari M.B.A., Ph.D.,
  Chief Devel. Officer
• Dr. Sydney D. Finkelstein,
  Chief Scientific Officer
• Thomas John Freeburg Ph.D.,
  CFO, Treasurer & Sec.
• Nat Krishnamurti,
  Interim CFO
• Graham G Miao,
  CFO
• William Jheartland Advisors...,
  
• Harry Glorikian,
  Director
• 2018 Limited Partnership Am...,
  10% owner
• Thomas W. Burnell,
  President & CEO
• Peter Kamin,
  10% owner
• Laurence Mc Carthy,
  Director
• Felice Schnoll Sussman,
  Director
• Gregory Richard,
  Chief Commerical Officer
• James Early,
  
• Vijay Aggarwal,
  Director
• Christopher Mc Carthy,
  Chief Financial Officer